Samarqand

Researchers are evaluating the efficacy and safety of the drug Reamberin solution for infusion, 1.5%, for treating viral enteric infection in children aged 1 to 6 years. This study focuses on children of both sexes diagnosed with viral and other specified intestinal infections who show clinical signs of endogenous intoxication and require infusion therapy. The trial aims to understand how well Reamberin works and how safe it is when used as part of routine clinical care. Participants receive Reamberin at a daily dose of 10 mL per kg of body weight along with fluids such as normal saline, glucose solutions, or Ringer's solution. The treatment is given by infusion under the supervision of a physician. The study is observational, involving monitoring children who have been prescribed Reamberin and supportive fluids as part of their treatment. During the study, researchers assess how many children continue infusion therapy at 24 and 48 hours after starting treatment, the average duration of infusion therapy, and symptom duration related to gastrointestinal damage and intoxication. They also evaluate the severity of illness 48 hours after treatment begins and how long children stay in the hospital. Parents or legal representatives provide informed consent, and the total participation includes treatment and monitoring of outcomes in a clinical setting.

Researchers are investigating the links between coronary heart disease and anxiety disorders, focusing on patients with unstable angina pectoris and associated anxiety-depressive syndrome. The study includes 202 patients aged 30 to 88 years with coronary artery disease, divided into a control group with stable angina and a main group with unstable angina. The research aims to better understand the immunological and psychological features of these conditions and their interactions over a long period from 2019 to 2027. Participants provide fasting blood samples to measure levels of cytokines (TNF-b1, IL-1b2, IL-4, and IL-10) using enzyme-linked immunosorbent assay (ELISA) and uric acid levels using a standard method. Patients with unstable angina receive conventional therapy including nitrates, beta-blockers, ACE inhibitors or sartans, antiplatelet agents, anticoagulants, clopidogrel, and statins. Those with elevated uric acid are treated with Febuxostat. Additionally, patients diagnosed with anxiety-depressive syndrome are given Divase syndrome, a medication with neurotropic and antioxidant effects. During the study, participants complete anxiety and depression assessments including the hospital anxiety and depression scale and the Spielberger-Khanin anxiety scale to evaluate cognitive function and anxiety levels. Measurements are taken periodically throughout the 2019-2027 study period. Researchers monitor cytokine levels, anxiety and depression symptoms, and overall clinical status to understand the interaction between coronary heart disease and mental health, with participants having the option to withdraw at any time.